Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Background: Pembrolizumab leads to responses in 20-30% of metastatic bladder cancer patients. Irradiation of bladder cancer cells in-vitro and in-vivo leads to upregulation of PD-L1, and in immunocompetent mouse models blockade of PD-L1 leads to longer tumour growth delay following irradiation. A trial of chemoradiotherapy with pembrolizumab in muscle invasive localised bladder cancer will assess safety and synergy of the combination.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
